Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission
- Badavanis, George;
- Pasmatzi, Efstathia;
- Kapranos, Nikiforos;
- Monastirli, Alexandra;
- Tsambaos, Dionysios
Published Web Locationhttps://doi.org/10.5070/D3246040714
Erythema multiforme is an immune-mediated cutaneous disorder that is thought to represent a hypersensitivity reaction to infections, drugs, vaccines, malignancies, autoimmune diseases, radiation, and menstruation. Golimumab is a human IgG1-kappa anti-TNF antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. We report herein a 41-year-old woman with persistent erythema multiforme, that occurred 18 months after onset of golimumab treatment of her ulcerative colitis; the latter remains in full remission over a period of 36 months.